Cargando…

Patient expectations and experiences of multiple sclerosis interferon β-1a treatment: a longitudinal, observational study in routine UK clinical practice

BACKGROUND: Premature discontinuation and poor treatment adherence are problems in chronic conditions, such as multiple sclerosis in which patients must take long-term treatment in order to receive maximum benefit from their medication. The Assessing needs In Multiple Sclerosis (AIMS) study explored...

Descripción completa

Detalles Bibliográficos
Autores principales:	Syed, Mehmood, Rog, David, Parkes, Laura, Shepherd, Gillian L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933729/ https://www.ncbi.nlm.nih.gov/pubmed/24570582 http://dx.doi.org/10.2147/PPA.S46421

Ejemplares similares

Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland
por: D’Arcy, Caroline, et al.
Publicado: (2012)

Oral contraceptives combined with interferon β in multiple sclerosis
por: Pozzilli, Carlo, et al.
Publicado: (2015)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Interferon Treatment of Multiple Sclerosis
por: Alajbegovic, Azra, et al.
Publicado: (2012)

Early stage and long term treatment of multiple sclerosis with interferon-β
por: Applebee, Angela, et al.
Publicado: (2009)

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
por: Kolb-Mäurer, Annette, et al.
Publicado: (2015)

Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis
por: Jandric, Danka, et al.
Publicado: (2021)

Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
por: Molnarfi, Nicolas, et al.
Publicado: (2012)

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
por: Hegen, Harald, et al.
Publicado: (2016)

Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data
por: Moccia, Marcello, et al.
Publicado: (2021)

Epidemiology of multiple sclerosis: results from a large observational study in the UK
por: Jick, Susan S., et al.
Publicado: (2015)

Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008)

Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis
por: Zhornitsky, Simon, et al.
Publicado: (2015)

Bone marrow sarcoidosis associated with long‐term interferon‐β treatment for multiple sclerosis
por: Teh, Angela, et al.
Publicado: (2016)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
por: Simpson-Yap, Steve, et al.
Publicado: (2022)

Endogenous Interferon-β-Inducible Gene Expression and Interferon-β-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2015)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Portuguese validation of the credibility/expectancy questionnaire in routine practice
por: Silva, Sara, et al.
Publicado: (2021)

Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data
por: Hardy, Todd A, et al.
Publicado: (2022)

Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis
por: Gandhi, Kaushal S., et al.
Publicado: (2010)

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β
por: De Felice, Bruna, et al.
Publicado: (2014)

Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis
por: Liao, Ming-Feng, et al.
Publicado: (2013)

Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis
por: Yetkin, Mehmet Fatih, et al.
Publicado: (2016)

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
por: Furber, Kendra L, et al.
Publicado: (2017)

Physical activity, multimorbidity, and life expectancy: a UK Biobank longitudinal study
por: Chudasama, Yogini V., et al.
Publicado: (2019)

Patient Attitudes to Routine Cognitive Testing in Multiple Sclerosis
por: Mortensen, Gitte Lee, et al.
Publicado: (2020)

An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device
por: Willis, Helen, et al.
Publicado: (2014)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Identifying responders and nonresponders to interferon therapy in multiple sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK
por: Mazibrada, Gordon, et al.
Publicado: (2018)

Longitudinal study of alexithymia and multiple sclerosis
por: Chahraoui, Khadija, et al.
Publicado: (2014)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Peripheral Vasculitis, Intermediate Uveitis and Interferon Use in Multiple Sclerosis
por: Kinyas, Şeref, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q4tjl1fl39bhvv7cricotpatoc